TY  - JOUR
A1  - Dütting, Sebastian
A1  - Gaits-Iacovoni, Frederique
A1  - Stegner, David
A1  - Popp, Michael
A1  - Antkowiak, Adrien
A1  - van Eeuwijk, Judith M.M.
A1  - Nurden, Paquita
A1  - Stritt, Simon
A1  - Heib, Tobias
A1  - Aurbach, Katja
A1  - Angay, Oguzhan
A1  - Cherpokova, Deya
A1  - Heinz, Niels
A1  - Baig, Ayesha A.
A1  - Gorelashvili, Maximilian G.
A1  - Gerner, Frank
A1  - Heinze, Katrin G.
A1  - Ware, Jerry
A1  - Krohne, Georg
A1  - Ruggeri, Zaverio M.
A1  - Nurden, Alan T.
A1  - Schulze, Harald
A1  - Modlich, Ute
A1  - Pleines, Irina
A1  - Brakebusch, Cord
A1  - Nieswandt, Bernhard
T1  - A Cdc42/RhoA regulatory circuit downstream of glycoprotein Ib guides transendothelial platelet biogenesis
JF  - Nature Communications
N2  - Blood platelets are produced by large bone marrow (BM) precursor cells, megakaryocytes (MKs), which extend cytoplasmic protrusions (proplatelets) into BM sinusoids. The molecular cues that control MK polarization towards sinusoids and limit transendothelial crossing to proplatelets remain unknown. Here, we show that the small GTPases Cdc42 and RhoA act as a regulatory circuit downstream of the MK-specific mechanoreceptor GPIb to coordinate polarized transendothelial platelet biogenesis. Functional deficiency of either GPIb or Cdc42 impairs transendothelial proplatelet formation. In the absence of RhoA, increased Cdc42 activity and MK hyperpolarization triggers GPIb-dependent transmigration of entire MKs into BM sinusoids. These findings position Cdc42 (go-signal) and RhoA (stop-signal) at the centre of a molecular checkpoint downstream of GPIb that controls transendothelial platelet biogenesis. Our results may open new avenues for the treatment of platelet production disorders and help to explain the thrombocytopenia in patients with Bernard–Soulier syndrome, a bleeding disorder caused by defects in GPIb-IX-V.
KW  - megakaryocytes
KW  - blood platelets
KW  - regulatory circuit downstream
KW  - glycoprotein Ib
Y1  - 2017
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-170797
VL  - 8
IS  - 15838
ER  - 
TY  - JOUR
A1  - Beck, Sarah
A1  - Stegner, David
A1  - Loroch, Stefan
A1  - Baig, Ayesha A.
A1  - Göb, Vanessa
A1  - Schumbutzki, Cornelia
A1  - Eilers, Eva
A1  - Sickmann, Albert
A1  - May, Frauke
A1  - Nolte, Marc W.
A1  - Panousis, Con
A1  - Nieswandt, Bernhard
T1  - Generation of a humanized FXII knock-in mouse-A powerful model system to test novel anti-thrombotic agents
JF  - Journal of Thrombosis and Haemostasis
N2  - Background
Effective inhibition of thrombosis without generating bleeding risks is a major challenge in medicine. Accumulating evidence suggests that this can be achieved by inhibition of coagulation factor XII (FXII), as either its knock-out or inhibition in animal models efficiently reduced thrombosis without affecting normal hemostasis. Based on these findings, highly specific inhibitors for human FXII(a) are under development. However, currently, in vivo studies on their efficacy and safety are impeded by the lack of an optimized animal model expressing the specific target, that is, human FXII.

Objective
The primary objective of this study is to develop and functionally characterize a humanized FXII mouse model.

Methods
A humanized FXII mouse model was generated by replacing the murine with the human F12 gene (genetic knock-in) and tested it in in vitro coagulation assays and in in vivo thrombosis models.

Results
These hF12\(^{KI}\) mice were indistinguishable from wild-type mice in all tested assays of coagulation and platelet function in vitro and in vivo, except for reduced expression levels of hFXII compared to human plasma. Targeting FXII by the anti-human FXIIa antibody 3F7 increased activated partial thromboplastin time dose-dependently and protected hF12\(^{KI}\) mice in an arterial thrombosis model without affecting bleeding times.

Conclusion
These data establish the newly generated hF12\(^{KI}\) mouse as a powerful and unique model system for in vivo studies on anti-FXII(a) biologics, supporting the development of efficient and safe human FXII(a) inhibitors.
KW  - hemostasis,
KW  - blood coagulation
KW  - factor XII
KW  - animal models
KW  - thrombosis
Y1  - 2021
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-259567
VL  - 19
IS  - 11
ER  -